HIF1A and neoplasm: Kheshtchin et al. [221] reported that the combination of DC-based vaccination and PX-478, an inhibitor of oxygen-sensitive HIF-1α, enhances T cell effector functions and leads to inhibited tumor growth and enhanced survival in breast cancer mouse model.